Year

2009

Status

Exited

Team

Field

Antibody technology platform

Location

Rotterdam (The Netherlands), Gent (Belgium)

Fund

BGV I

arGEN-X

arGEN-X employs a superior therapeutic antibody platform for the generation of human monoclonal antibodies. arGen-X
successfully completed an IPO in 2014 at EuroNext Brussels.